Ligand Pharmaceuticals (LGND) Return on Capital Employed Growth (1y) (2012 - 2026)
Ligand Pharmaceuticals (LGND) Return on Capital Employed Growth (1y) (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,899.61 Bn | 65,899.33 Bn | - | 1,648.00 |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | 31,429.00 |
| 4 | BeOne Medicines | 471.67 Bn | 466.88 Bn | 1.35 Bn | 1,805.00 |
| 5 | Vertex Pharmaceuticals | 122.32 Bn | 115.07 Bn | 2.59 Bn | 2,503.00 |
| 6 | Regeneron Pharmaceuticals | 70.04 Bn | 61.29 Bn | 3.31 Bn | -105.00 |
| 7 | Belite Bio | 62.06 Bn | 62.06 Bn | - | - |
| 8 | Argenx Se | 55.93 Bn | 50.74 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.55 Bn | 34.54 Bn | 959.66 Mn | 2,400.00 |
| 10 | Ligand Pharmaceuticals | 5.85 Bn | 5.07 Bn | 48.45 Mn | 1,343.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1,343.00 |
| Dec 31, 2025 | 525.00 |
| Sep 30, 2025 | 333.00 |
| Jun 30, 2025 | -209.00 |
| Mar 31, 2025 | -723.00 |
| Dec 31, 2024 | -405.00 |
| Sep 30, 2024 | -120.00 |
| Jun 30, 2024 | -247.00 |
| Mar 31, 2024 | -211.00 |
| Dec 31, 2023 | 119.00 |
| Sep 30, 2023 | -719.00 |
| Jun 30, 2023 | -636.00 |
| Mar 31, 2023 | -654.00 |
| Dec 31, 2022 | -797.00 |
| Sep 30, 2022 | -69.00 |
| Jun 30, 2022 | 66.00 |
| Mar 31, 2022 | 562.00 |
| Dec 31, 2021 | 524.00 |
| Sep 30, 2021 | 688.00 |
| Jun 30, 2021 | 668.00 |